Immune checkpoint inhibitor therapy-induced autoimmune polyendocrine syndrome typeⅡand Crohn's disease:A case report  

作　　者：Mei-Juan Gao Yan Xu Wen-Bo Wang 

机构地区：[1]Department of Endocrinology,Peking University Shougang Hospital,Beijing 100041,China

出　　处：《World Journal of Clinical Cases》2023年第14期3267-3274,共8页世界临床病例杂志

摘　　要：BACKGROUND The development of immune checkpoint inhibitors(ICIs)has heralded a new era in cancer treatment,enabling the possibility of long-term survival in patients with metastatic disease.Unfortunately,ICIs are increasingly implicated in the development of autoimmune diseases.CASE SUMMARY We present a man with squamous cell carcinoma of the oropharynx on a combination of teriprizumab,docetaxel,and cisplatin therapy who developed autoimmune polyendocrine syndrome typeⅡ(APS-2)including thyroiditis and type 1 diabetes mellitus and Crohn’s disease(CD).He developed thirst,abdominal pain,and fatigue after two-week treatment with the protein 1 ligand inhibitor teriprizumab.Biochemistry confirmed APS-2 and thyrotoxicosis.He was commenced on an insulin infusion.However,his abdominal pain persisted.Follow-up surgery confirmed CD and his abdominal pain was relieved by mesalazine.He was continued on insulin and mesalazine therapy.CONCLUSION Immunotherapy can affect all kinds of organs.When clinical symptoms cannot be explained by a single disease,clinicians should consider the possibility of multisystem damage.

关 键 词：Immune checkpoint inhibitor Programmed cell death protein 1 ligand Autoimmune polyendocrine syndrome type II Type 1 diabetes mellitus Thyroiditis Crohn’s disease Case report 

分 类 号：R593.2[医药卫生—内科学] R574[医药卫生—临床医学]